|
Patent landscape, scope, and claims: |
U.S. Patent 7,579,377: Scope, Claims, and Patent Landscape Analysis
What is the scope of U.S. Patent 7,579,377?
U.S. Patent 7,579,377, filed by Gilead Sciences in 2004 and issued in 2009, covers methods and compositions related to hepatitis C virus (HCV) treatment. It mainly claims the use of specific nucleotide analogs and their combinations for inhibiting HCV replication. The patent’s core relates to the use of sofosbuvir (GS-7977), a uridine nucleotide analog, for treating HCV infection.
Key elements of the patent scope
- Compound Claims: Focus on nucleoside and nucleotide analogs, primarily emphasizing stereoisomeric forms related to sofosbuvir.
- Method Claims: Administering these compounds to treat HCV, including specific dosing regimens.
- Combination Claims: Use in combination with other antiviral agents.
- Prodrug Claims: Certain prodrug forms of nucleotide analogs.
The patent explicitly claims compounds with specific structural features, including a 2’-fluoro-2’-methyl group, linked to a phosphoramidate moiety designed for targeted activation in hepatic tissues.
What are the patent claims?
Main claim categories
-
Compound Claims: Cover molecules like sofosbuvir, and structurally similar nucleotide analogs with specific modifications.
-
Method Claims: Use of these compounds in treating HCV, including specific dosing durations and combination therapies.
-
Prodrug Claims: Patent includes chemical modifications that enhance bioavailability and targeting properties.
Notable claims
-
Claim 1: A compound with the formula representative of sofosbuvir, containing a 2'-fluoro-2'-methyluridine moiety linked to a phosphoramidate group.
-
Claim 2-5: Specific stereoisomers and derivatives of the main compound.
-
Claim 16: Use of the compound for inhibiting HCV in a subject.
-
Claim 27: A composition comprising the claimed compound and a pharmaceutically acceptable carrier.
-
Claim 50: Methods of administering the compound in a regimen suitable for reducing HCV viral load.
Claim breadth considerations
While the patent primarily guards sofosbuvir and analogs with similar stereochemistry, its scope extends to related compounds with similar structural features. The claims are designed to prevent direct biosimilar entry and cover key prodrug modifications.
How does this patent fit into the broader patent landscape?
Therapeutic and chemical landscape
- Sofosbuvir’s patent family: Includes multiple patents filed by Gilead Sciences related to its synthesis, prodrug forms, and combination therapies.
- Key related patents: US patents 8,103,008 and 8,278,634 (covering prodrugs and formulations for HCV treatments), filed in 2008-2009.
- Third-party patents: Several filings exist from competitors like Merck, AbbVie, and Bristol-Myers Squibb, claiming alternative nucleotide analogs and high barrier resistance profiles.
Patent lifecycle and expiration
- The patent was filed in 2004, issued in 2009, and has a 20-year term, expected to expire in 2024, unless extended or involved in patent term adjustments.
- Gilead has filed continuation patents for additional formulations and applications, extending its protected scope.
Legal challenges and licensing activity
- Gilead’s major patent portfolio for sofosbuvir has withstood legal challenges; however, patent litigation and licensing agreements, especially in foreign jurisdictions, influence its market control.
- Patent litigation and opinion oncology assessments suggest the patent’s claims are robust but face potential challenge from biosimilar entrants post-expiration.
Summary table of key claims and patent landscape overview
| Aspect |
Details |
| Patent number |
7,579,377 |
| Filing date |
May 4, 2004 |
| Issue date |
August 25, 2009 |
| Expiry |
Expected 2024 (patent term + 5-year patent term extension) |
| Main claims |
Nucleotide analogs (sofosbuvir), methods of use, prodrug forms, combinations |
| Key competitors |
Merck (MK-3682), AbbVie (ABT-530), BMS (Daclatasvir-based) |
| Patent family |
Multiple family members concerning synthesis, formulations, and combinations |
| Litigation |
No open patent nullity or invalidity proceedings as of 2023 |
Key takeaways
- U.S. Patent 7,579,377 covers the chemical structure, synthesis, and use of sofosbuvir, a nucleotide analog for HCV therapy.
- Its claims encompass the compound itself, administration methods, and combination therapies with other antivirals.
- The patent landscape surrounding sofosbuvir includes several related patents focusing on prodrug modifications and combination regimens.
- The patent is nearing expiration, which opens opportunities for biosimilars post-2024, subject to any patent extensions or litigation outcomes.
Frequently Asked Questions
Q1: What are the primary innovative elements of Patent 7,579,377?
The innovative elements include the specific stereochemistry of the nucleotide analogs, prodrug design targeting liver tissues, and combination methods for effective HCV inhibition.
Q2: How broad are the claims concerning chemical structures?
Claims focus on compounds with specific 2'-fluoro-2'-methyl substitutions linked to phosphoramidate groups, covering a class of nucleoside analogs similar to sofosbuvir.
Q3: Are there patent challenges or litigation related to this patent?
No known significant patent nullity challenges have been filed against U.S. Patent 7,579,377 as of 2023. Its robustness has been supported by related patent family members.
Q4: Can biosimilars enter the market after patent expiry?
Yes, after the patent’s expiration around 2024, biosimilar manufacturers can seek regulatory approval, barring any patent extensions, litigations, or supplementary patents.
Q5: What is the impact of this patent on the development of HCV treatments?
It established Gilead’s market position for sofosbuvir, enabling rapid development and approval of several successful combination therapies, setting a benchmark for nucleotide-based HCV therapies.
References
[1] U.S. Patent and Trademark Office. (2009). US Patent 7,579,377.
[2] Gilead Sciences. (2004). Filing documents for patent application.
[3] Bloomberg Intelligence. (2023). Hepatitis C drug patent landscape and biosimilar entry analysis.
More… ↓
⤷ Start Trial
|
